EU Council Calls for Discussions On New Pricing Mechanisms
Executive Summary
Transparency on pricing and cost calculations could improve and inform public policy on medicines access, say EU health ministers.
You may also be interested in...
EU Council Agrees Compromise Position On Joint Clinical Assessments
The Alliance For Regenerative Medicines is calling for advanced therapies to be given greater priority where joint clinical assessments are concerned.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.